Catheter-induced left main dissection: a treatment dilemmaNiall T Mulvihill
Unite de Cardiologie Interventionelle, Clinique Pasteur, Toulouse, France
Catheter Cardiovasc Interv 59:214-6. 2003
..However, there are potential life threatening complications which can occasionally occur. We describe one such complication and detail the management and clinical outcome...
- Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial
Jean Fajadet
Clinique Pasteur, 45, Avenue du Lombez, 31300 Toulouse, France
Circulation 111:1040-4. 2005
..This analysis examined whether these beneficial effects persist over the longer term...
- Thirty-day outcome and vascular complications after transarterial aortic valve implantation using both Edwards Sapien and Medtronic CoreValve bioprostheses in a mixed population
Didier Tchetche
Clinique Pasteur, Toulouse, France
EuroIntervention 5:659-65. 2010
..We report 30-day data from a mixed population of patients treated with either Medtronic CoreValve (MCV) or Edwards SAPIEN (ES) valves...
Stent implantation in aorto-ostial lesions: long-term follow-up and predictors of outcomeAndre Luz
Clinique Pasteur, Toulouse, France
EuroIntervention 7:1069-76. 2012
..To compare the outcomes of drug-eluting (DES) vs. bare-metal (BMS) stents for stenting of native aorto-ostial lesions (AOL) and to identify predictors of major adverse cardio and cerebrovascular events (MACCE)...
- Adverse impact of bleeding and transfusion on the outcome post-transcatheter aortic valve implantation: insights from the Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC Plus) initiative
Didier Tchetche
Clinique Pasteur, Toulouse, France
Am Heart J 164:402-9. 2012
..Little is known about the impact of bleeding and red blood cells transfusion (RBC) on the outcome post transcatheter aortic valve implantation (TAVI)...
- Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial
Jean Fajadet
Clinique Pasteur, Toulouse, France
Circulation 114:798-806. 2006
..0001). CONCLUSIONS: Compared with bare metal stents, the Endeavor stent is safe and reduces the rates of clinical and angiographic restenosis at 9, 12, and 24 months...
- Long-term follow-up of percutaneous coronary intervention of unprotected left main lesions with drug eluting stents: predictors of clinical outcome
Andrea Pavei
Clinique Pasteur, Toulouse, France
EuroIntervention 4:457-63. 2009
..To evaluate the long-term follow-up of drug-eluting stents (DES) in the treatment of unprotected left main coronary artery (ULMCA)...
- Percutaneous treatment of coronary subclavian steal syndrome
Niall T Mulvihill
Unite de Cardiologie Interventionelle, Clinique Pasteur, Toulouse, France
J Invasive Cardiol 15:390-2. 2003
..This syndrome can be successfully treated percutaneously with excellent immediate and long-term results...
- Current management of left main coronary artery disease
Jean Fajadet
Clinique Pasteur, Toulouse, France
Eur Heart J 33:36-50b. 2012
..Further randomized trials must be conducted to precise the indications of both techniques of revascularization in the treatment of LM disease...
- Impact of restenosis and disease progression on clinical outcome after multivessel stenting in diabetic patients
Mohamed Loutfi
Unite de Cardiologie Interventionelle, Clinique Pasteur, Toulouse, France
Catheter Cardiovasc Interv 58:451-4. 2003
..Consequently, even if drug-eluting stent technology can eliminate restenosis, disease progression will continue to impact the clinical outcome of diabetic patients after PCI...
- Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study
Jean Fajadet
Clinique Pasteur, Toulouse, France
EuroIntervention 6:562-7. 2010
....
- Update on the need for a permanent pacemaker after transcatheter aortic valve implantation using the CoreValve® Accutrak™ system
Didier Tchetche
Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France
EuroIntervention 8:556-62. 2012
..The aims of this paper were to describe the potential impact of the Accutrak™ catheter on the accuracy of positioning a 26 or 29 mm CoreValve® across the aortic annulus and its impact on the need for a pacemaker...
- Rapid sealing of coronary perforations using polytetrafluoroethylene-covered stents
Niall T Mulvihill
Unite De Cardiologie Interventionnelle, Clinique Pasteur, Toulouse, France
Am J Cardiol 91:343-6. 2003
- Impact of stable versus unstable coronary artery disease on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents: a subanalysis of the ARTS II trial
Marco Valgimigli
Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
J Am Coll Cardiol 49:431-41. 2007
....
- A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization
Marie-Claude Morice
Institut Cardiovasculaire Paris Sud, Massy, France
N Engl J Med 346:1773-80. 2002
..CONCLUSIONS: As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events...
- Triple vessel stenting for triple vessel coronary disease
Beatriz Villegas
Institut Cardiovasculaire Paris Sud, 6 avenue du Noyer Lambert, 91300, Massy, France
J Invasive Cardiol 14:1-5. 2002
..Most eligible patients underwent uncomplicated and immediately successful procedures. The long-term outcome was comparable to controlled studies of CABG, except for a higher rate of repeat revascularization procedures due to restenosis...
- Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial)
Ryota Sakurai
Center for Cardiovascular Technology, Stanford University Medical Center, Stanford, California, USA
Am J Cardiol 100:818-23. 2007
..In conclusion, ZES showed evenly inhibited neointima with no apparent adverse vascular response in stented and reference segments at 8 months compared with BMS...
- [Prognosis after acute coronary syndrome. Lack of difference according to the sex]
Jean-Paul Bounhoure
, , 1, avenue Jean Poulhes Toulouse 31403
Bull Acad Natl Med 188:383-97; discussion 397-9. 2004
..Women with ACS who are at high risk derive the same benefit as men from early angioplasty and coronary stenting of the culprit lesion, with satisfactory in-hospital and mid-term outcomes...
- Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients
Anthony Gershlick
University Hospitals of Leicester School of Medicine, Leicester, United Kingdom
Am J Cardiol 100:45M-55M. 2007
....
- Effects of selective alpha1- and alpha2-adrenergic blockade on coronary flow reserve after coronary stenting
Luisa Gregorini
Experimental Surgery and Transplantation Institute, Ospedale Maggiore IRCCS, University of Milano, Italy
Circulation 106:2901-7. 2002
..Coronary flow reserve (CFR) is not normalized shortly after coronary stenting. We hypothesized that alpha-adrenergic coronary vasoconstriction acts to limit CFR...
- High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial
Eberhard Grube
J Am Coll Cardiol 44:1368-72. 2004
..Santa Clara, California/Boston Scientific Corp., Natick, Massachusetts) versus uncoated control stents (n = 140) in focal, de novo coronary lesions...
